Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.84) by 28.57 percent. This is a 30.43 percent decrease over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $45.35 million which missed the analyst consensus estimate of $47.68 million by 4.88 percent. This is a 38.19 percent decrease over sales of $73.37 million the same period last year.
IN8bio, Inc. – Common Stock Q2 EPS $(0.38) Up From $(1.00) YoY
IN8bio, Inc. - Common Stock (NASDAQ:INAB) reported quarterly losses of $(0.38) per share. This is a 62 percent increase over losses of $(1.00) per share from the same period last year.
